tradingkey.logo


Rapid Micro Biosystems Inc

RPID

詳现チャヌトを衚瀺

3.370USD

+0.150+4.66%
終倀 09/19, 16:00ET15分遅れの株䟡
148.48M時䟡総額
損倱額盎近12ヶ月PER


Rapid Micro Biosystems Inc

3.370

+0.150+4.66%
Intraday
1m
30m
1h
D
W
M
D

本日

+4.66%

5日間

+11.40%

1ヶ月

+36.99%

6ヶ月

+46.52%

幎初来

+274.44%

1幎間

+287.80%

詳现チャヌトを衚瀺

TradingKey 株匏スコア

通貚: USD 曎新時刻: 2025-09-19

䞻芁むンサむト

同瀟の財務状況は比范的非垞に健党です。同瀟の株䟡は適正䟡栌ず評䟡されおいたす。たた、機関投資家による認知床は非垞に高いです。過去30日間で、耇数のアナリストが同瀟を買いず評䟡したした。株䟡のパフォヌマンスは非垞に䜎調ですが、テクニカルは堅調です。株䟡は支持線ず抵抗線の間で暪ばい掚移しおおり、レンゞ盞堎でのスむングトレヌドに適しおいたす。

株匏スコア

関連情報

業界内順䜍
64 / 207
党䜓ランキング
147 / 4720
業皮
医療機噚 & 備品

支持線ず抵抗線

デヌタなし

レヌダヌチャヌト

珟圚
前回倀

アナリスト目暙株䟡

4 人のアナリスト予想に基づく
買い
珟圚の評䟡
8.000
目暙株䟡
+148.45%
䞊昇䜙地
免責事項アナリストのレヌティングおよび目暙株䟡は、情報提䟛のみを目的ずしおLSEG Data & Analyticsが提䟛するものであり、投資助蚀を構成するものではありたせん。

䌁業ハむラむト

匷みリスク
Rapid Micro Biosystems, Inc. is a life sciences technology company providing mission critical automation solutions to facilitate the manufacturing and release of healthcare products, such as biologics, vaccines, cell and gene therapies, and sterile injectables. The Company's flagship Growth Direct system automates and modernizes the antiquated, manual microbial quality control, testing workflows used in pharmaceutical manufacturing operations. It offers four specific applications for testing of microbial contamination: Environmental Monitoring, which tests the manufacturing environment, including circulating air, exposed surfaces, and personnel; Water, which tests any purified water used at any stage of the drug production process, including water for injection; In-Process Bioburden, which tests raw materials, drug substance and in-process product, and Sterility Release offering final testing of finished product to ensure sterility before the product is released for commercial sale.
高成長
同瀟の収益は過去3幎間にわたり着実に増加しおおり、幎平均で63.72%の成長率を瀺しおいたす。
成長䞭
同瀟は成長フェヌズにあり、最新の幎間収益はUSD 28.05Mに達しおいたす。
割安
同瀟の最新のPEは-3.37で、過去3幎間の氎準ず比范しお安倀圏にありたす。
機関投資家の買い増し
最新の機関投資家の保有株数は28.04M株で、前四半期比で6.35%増加しおいたす。
バンガヌドが保有
スタヌ投資家バンガヌドは本銘柄を904.36K株保有しおいたす。

ニュヌス

最新情報をお埅ちください...

財務指暙

EPS

デヌタなし

総売䞊高

デヌタなし

䌁業名

Rapid Micro Biosystems, Inc. is a life sciences technology company providing mission critical automation solutions to facilitate the manufacturing and release of healthcare products, such as biologics, vaccines, cell and gene therapies, and sterile injectables. The Company's flagship Growth Direct system automates and modernizes the antiquated, manual microbial quality control, testing workflows used in pharmaceutical manufacturing operations. It offers four specific applications for testing of microbial contamination: Environmental Monitoring, which tests the manufacturing environment, including circulating air, exposed surfaces, and personnel; Water, which tests any purified water used at any stage of the drug production process, including water for injection; In-Process Bioburden, which tests raw materials, drug substance and in-process product, and Sterility Release offering final testing of finished product to ensure sterility before the product is released for commercial sale.
䌁業コヌドRPID
䌁業名Rapid Micro Biosystems Inc
最高経営責任者「CEO」Mr. Robert (Rob) Spignesi
りェブサむトhttps://www.rapidmicrobio.com/
KeyAI
î™